Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions

被引:28
|
作者
Zhang, Yiyin [1 ,2 ,3 ,4 ]
Yang, Chao [1 ,2 ,3 ,4 ]
Cheng, He [1 ,2 ,3 ,4 ]
Fan, Zhiyao [1 ,2 ,3 ,4 ]
Huang, Qiuyi [1 ,2 ,3 ,4 ]
Lu, Yu [1 ,2 ,3 ,4 ]
Fan, Kun [1 ,2 ,3 ,4 ]
Luo, Guopei [1 ,2 ,3 ,4 ]
Jin, Kaizhou [1 ,2 ,3 ,4 ]
Wang, Zhengshi [1 ,2 ,3 ,4 ]
Liu, Chen [1 ,2 ,3 ,4 ]
Yu, Xianjun [1 ,2 ,3 ,4 ]
机构
[1] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat Surg, 270 DongAn Rd, Shanghai 200032, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, 270 DongAn Rd, Shanghai 200032, Peoples R China
[3] Shanghai Pancreat Canc Inst, 270 DongAn Rd, Shanghai 200032, Peoples R China
[4] Fudan Univ, Pancreat Canc Inst, 270 DongAn Rd, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
Pancreatic ductal adenocarcinoma; Novel regimens; Biomarkers; Combination therapies; GEMCITABINE PLUS PLACEBO; PHASE-II TRIAL; ALGENPANTUCEL-L IMMUNOTHERAPY; STANDARD ADJUVANT THERAPY; DOUBLE-BLIND; MESENCHYMAL TRANSITION; E-CADHERIN; RESECTABLE ADENOCARCINOMA; PREOPERATIVE GEMCITABINE; IONIZING-RADIATION;
D O I
10.1186/s13045-017-0551-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation) therapy is the main treatment approach. However, gemcitabine-and 5-fluorouracil-based therapies did not present satisfying outcomes. Novel regimens targeting pancreatic cancer cells, the tumor microenvironment, and immunosuppression are emerging. Biomarkers concerning the treatment outcome and patient selection are being discovered in preclinical or clinical studies. Combination therapies of classic chemotherapeutic drugs and novel agents or novel therapeutic combinations might bring hope to the dismal prognosis for PDAC patients.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] A Novel Endoglin Variant in Pancreatic Ductal Adenocarcinoma
    Kumar, Sanjay
    Shah, Nirav
    Zaman, Naveed
    Lee, Nam Y.
    FASEB JOURNAL, 2017, 31
  • [22] Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma
    Ahn, Daniel H.
    Ramanathan, Ramesh K.
    Bekaii-Saab, Tanios
    CANCERS, 2018, 10 (06)
  • [23] Pathogenesis of the ductal pancreatic adenocarcinoma: Implications for future therapies?
    Schneider, G
    Schmid, R
    INTERNIST, 2005, 46 (02): : 157 - +
  • [24] Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives
    Tiwari, Akash
    Kumar, Lalit
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2018, 148 (03) : 254 - 257
  • [25] Neoadjuvant treatment of pancreatic ductal adenocarcinoma: present and future
    Koukourakis, Ioannis M.
    Desse, Dimitra
    Papadimitriou, Marios
    Konstadoulakis, Manousos
    Zygogianni, Anna
    Papadimitriou, Christos
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2022, 8
  • [26] Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts
    Ruess, Dietrich A.
    Goerguelue, Kivanc
    Woermann, Sonja M.
    Alguel, Hana
    DRUGS & AGING, 2017, 34 (05) : 331 - 357
  • [27] Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts
    Dietrich A. Ruess
    Kivanc Görgülü
    Sonja M. Wörmann
    Hana Algül
    Drugs & Aging, 2017, 34 : 331 - 357
  • [28] Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia
    Creeden, Justin F.
    Alganem, Khaled
    Imami, Ali S.
    Henkel, Nicholas D.
    Brunicardi, F. Charles
    Liu, Shi-He
    Shukla, Rammohan
    Tomar, Tushar
    Naji, Faris
    McCullumsmith, Robert E.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 28
  • [29] Novel Agents in the Treatment of Pancreatic Adenocarcinoma
    Dimou, Anastasios
    Syrigos, Konstantinos N.
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2013, 14 (02): : 138 - 140
  • [30] Novel Agents for the Treatment of Pancreatic Adenocarcinoma
    Cheng, Haiying
    Merika, Eirini
    Syrigos, Kostas N.
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2011, 12 (04): : 334 - 338